Eating expectancies and hedonic hunger among individuals with bulimia‐spectrum eating disorders who plan binge‐eating episodes

Author(s):  
Megan N. Parker ◽  
Megan L. Wilkinson ◽  
Rowan A. Hunt ◽  
Alessandra Ortiz ◽  
Stephanie M. Manasse ◽  
...  
2013 ◽  
Vol 47 (3) ◽  
pp. 273-280 ◽  
Author(s):  
Ashley A. Witt ◽  
Michael R. Lowe

Author(s):  
Susan McElroy ◽  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Paul E. Keck

This chapter addresses the pharmacotherapy of the eating disorders (EDs). Many persons with EDs receive pharmacotherapy, but pharmacotherapy research for EDs has lagged behind that for other major mental disorders. This chapter first provides a brief rationale for using medications in the treatment of EDs. It then reviews the data supporting the effectiveness of specific medications or medication classes in treating patients with anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and other potentially important EDs, such as night eating syndrome (NES). It concludes by summarizing these data and suggesting future areas for research in the pharmacotherapy of EDs.


Author(s):  
Susan L. McElroy ◽  
Anna I. Guerdjikova ◽  
Anne M. O’Melia ◽  
Nicole Mori ◽  
Paul E. Keck

Many persons with eating disorders (EDs) receive pharmacotherapy, but pharmacotherapy research for EDs has lagged behind that for other major mental disorders. In this chapter, we first provide a brief rationale for using medications in the treatment of EDs. We then review the data supporting the effectiveness of specific medications or medication classes in treating patients with anorexia nervosa (AN), bulimia nervosa, binge eating disorder (BED), and other potentially important EDs, such as night eating syndrome (NES) and sleep-related eating disorder (SRED). We conclude by summarizing these data and suggesting future areas for research in the pharmacotherapy of EDs.


Appetite ◽  
2021 ◽  
pp. 105176
Author(s):  
Carla Loureiro Mourilhe Silva ◽  
Carlos Eduardo Ferreira de Moraes ◽  
Gloria Valeria da Veiga ◽  
Felipe Q. da Luz ◽  
Amanda Pompeu ◽  
...  

Author(s):  
Paul E. Jenkins

Abstract Purpose This study examined economic costs associated with untreated eating disorders (EDs) characterised by regular binge eating in the absence of low weight. Both direct and indirect costs were assessed, reporting a limited societal perspective of economic impact as some costs were not included. Methods One hundred and twenty six adults seeking treatment for recurrent binge eating were asked to report impairment associated with an ED. Costs were calculated using 2017 prices, including an examination of variables associated with costs. Results Estimated societal costs for the year preceding assessment were £3268.47 (€3758.54) per person. In multivariate analyses, no reliable baseline associates of cost were identified. Conclusion The economic burden of EDs characterised by regular binge eating is significant, and underscores the need for efficacious and cost-effective treatments. Individuals with binge-eating disorders report work impairment and healthcare use that may cost the United Kingdom economy upwards of £3.5 billion (€4bn) per annum. Further studies should consider academic impairment and the economic impact of EDs on families. Level of evidence III: evidence obtained from well-designed cohort or case–control analytic studies.


2017 ◽  
Vol 25 (6) ◽  
pp. 601-606 ◽  
Author(s):  
Trevor Steward ◽  
Gemma Mestre-Bach ◽  
Cristina Vintró-Alcaraz ◽  
Zaida Agüera ◽  
Susana Jiménez-Murcia ◽  
...  

1994 ◽  
Vol 2 (4) ◽  
pp. 355-363 ◽  
Author(s):  
Janet L. Guss ◽  
Harry R. Kissilejf ◽  
B. Timothy Walsh ◽  
Michael J. Devlin

Sign in / Sign up

Export Citation Format

Share Document